| 摘要 |
Variants of antibodies to human tissue factor are optimized for the capab ility to elicit effector functions produced by immune effector cells while m aintaining the ability to neutralize the biological functions of tissue fact or, such as the prevention of blood clotting via the extrinsic pathway, and are produced by mutations of the Fc-region of the antibody. The variants com prise A33 OY, A3301, and I332E where the I332E variant may optionally furthe r comprise a second substitution selected from A33OI (in the case of the fir st substitution being I332E), V264I, and S239D. The variants may further be optimized for the capability to elicit effector functions produced by immune effector cells by production of the antibody variants under conditions that produce effector function enhancing glycosylation of the Fc-region.
|
